{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=26", "query": { "condition": "Adenocarcinoma Lung", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 910, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:13:31.209Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00966914", "title": "Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel", "type": "DRUG" }, { "name": "Placebo in combination with cisplatin and docetaxel or paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNumerik Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2010-04", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2022-07-13", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Columbia, Missouri • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00966914" }, { "nct_id": "NCT01032850", "title": "Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Sorafenib & Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2009-09", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 3, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01032850" }, { "nct_id": "NCT01218516", "title": "A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Lung" ], "interventions": [ { "name": "Farletuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2011-06-27", "completion_date": "2013-11-01", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 54, "location_summary": "Chandler, Arizona • Glendale, Arizona • Beverly Hills, California + 50 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218516" }, { "nct_id": "NCT00970684", "title": "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nathan Pennell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2009-09", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2022-08-16", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 4, "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Mayfield Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970684" }, { "nct_id": "NCT00003649", "title": "Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Ad5CMV-p53 gene", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1998-11-17", "completion_date": "2007-06-15", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Green Bay, Wisconsin", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Green Bay", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003649" }, { "nct_id": "NCT00243685", "title": "Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Neoplasms", "Lung Neoplasms", "Ovarian Neoplasms", "Sarcoma, Soft Tissue" ], "interventions": [ { "name": "Laboratory Assay", "type": "OTHER" }, { "name": "Mick Assay", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pierian Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 150, "start_date": "2006-09", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-01-26", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 3, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243685" }, { "nct_id": "NCT00940225", "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2009-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 34, "location_summary": "Scottsdale, Arizona • Sacramento, California • San Francisco, California + 30 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00940225" }, { "nct_id": "NCT01327612", "title": "Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Carcinoid", "Colorectal Cancer", "Locally Advanced", "Lymphoma", "Metastatic Cancer", "Non-Small Cell Lung Cancer", "Sarcoma", "Solid Tumors" ], "interventions": [ { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "Conatumumab", "type": "BIOLOGICAL" }, { "name": "Ganitumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2011-03-03", "completion_date": "2020-02-05", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 10, "location_summary": "Duarte, California • La Jolla, California • Denver, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01327612" }, { "nct_id": "NCT01958372", "title": "Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Lung", "Adenosquamous Cell Lung Cancer", "Bronchoalveolar Cell Lung Cancer", "Large Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "soy isoflavones", "type": "DIETARY_SUPPLEMENT" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2014-08", "completion_date": "2019-11-11", "has_results": false, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 5, "location_summary": "Bay City, Michigan • Detroit, Michigan • Lapeer, Michigan + 2 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lapeer", "state": "Michigan" }, { "city": "Mount Pleasant", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01958372" }, { "nct_id": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cholangiocarcinoma", "Colorectal Cancer", "Head and Neck Neoplasms", "Lymphoma, Large-Cell, Anaplastic", "Melanoma", "Neuroendocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Papillary Thyroid Cancer", "Primary Brain Tumors", "Renal Cell Carcinoma", "Sarcomas", "Salivary Gland Cancers", "Adult Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2015-11-19", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-15T11:13:31.209Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568267" } ] }